Combination treatment may improve quality of life in kidney
This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries. Patients were required to be 18 years or older, with advanced clear-cell renal cell carcinoma, and a Karnofsky performance status of 70% or higher. Patients were randomly assigned (1:1:1) to lenvatinib + pembrolizumab + lenvatinib plus everolimus in 21-day cycles, or sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off). These HRQOL results demonstrate that patients given lenvatinib plus pembrolizumab treatment had similar or favourable scores compared with patients given sunitinib, particularly with respect to time to definitive deterioration. These results support the efficacy and safety profile of lenvatinib plus pembrolizumab as first-line therapy for patients with advanced renal cell carcinoma.